Harper was diagnosed as an infant with CDKL5, a rare genetic condition doctors only discovered in 2004 and that afflicts roughly 600 people worldwide. The disorder shares its name with the minute particle of DNA it affects, a gene responsible for the production of a protein crucial for neurological development. Symptoms of CDKL5 include intellectual disability, developmental delays, breathing and vision problems, limited or absent speech, poor muscle tone, and, perhaps worst of all, frequent seizures.
According to the United Nations Office on Drugs and Crime (UNODC), "the amount of THC present in a cannabis sample is generally used as a measure of cannabis potency." The three main forms of cannabis products are the flower, resin (hashish), and oil (hash oil). The UNODC states that cannabis often contains 5% THC content, resin "can contain up to 20% THC content", and that "Cannabis oil may contain more than 60% THC content."
Hemp seeds have an attractive nutty taste, and are now incorporated into many food preparations (Fig. 34), often mimicking familiar foods. Those sold in North America include nutritional (granola-type) or snack bars, “nut butters” and other spreads, bread, pretzels, cookies, yogurts, pancakes, porridge, fruit crumble, frozen dessert (“ice cream”), pasta, burgers, pizza, salt substitute, salad dressings, mayonnaise, “cheese,” and beverages (“milk,” “lemonade,” “beer,” “wine,” “coffee nog”). Hemp seed is often found canned or vacuum-packed (Fig. 35). Alcoholic beverages made with hemp utilize hempseed as a flavorant. Hemp food products currently have a niche market, based particularly on natural food and specialty food outlets.
Plastic composites for automobiles are the second most important component of the hemp industry of the EU. Natural fibers in automobile composites are used primarily in press-molded parts (Fig. 18). There are two widespread technologies. In thermoplastic production, natural fibers are blended with polypropylene fibers and formed into a mat, which is pressed under heat into the desired form. In thermoset production the natural fibers are soaked with binders such as epoxy resin or polyurethane, placed in the desired form, and allowed to harden through polymerization. Hemp has also been used in other types of thermoplastic applications, including injection molding. The characteristics of hemp fibers have proven to be superior for production of molded composites. In European manufacturing of cars, natural fibers are used to reinforce door panels, passenger rear decks, trunk linings, and pillars. In 1999 over 20,000 t of natural fiber were used for these purposes in Europe, including about, 2,000 t of hemp. It has been estimated that 5–10 kg of natural fibers can be used in the molded portions of an average automobile (excluding upholstery). The demand for automobile applications of hemp is expected to increase considerably, depending on the development of new technologies (Karus et al. 2000).
Jungmann and Thomas aren’t the only ones relying on China for their hemp supply. Today, Patagonia carries about two dozen products in hemp. Most are mixed with other materials, namely organic cotton. Jill Dumain, director of environmental strategy at Patagonia, developed the first hemp supply chain for the outdoor brand in the 1990s. She recalls trying to find suppliers of hemp fabrics in the US and getting frustrated because most of these suppliers were more interested in legalizing marijuana, rather than industrial hemp for fashion. When she requested cost estimates for fabric, she would get price sheets for puny quantities: five to 10 yards.
“Hemp” refers primarily to Cannabis sativa L. (Cannabaceae), although the term has been applied to dozens of species representing at least 22 genera, often prominent fiber crops. For examples, Manila hemp (abaca) is Musa textilis Née, sisal hemp is Agave sisalina Perrine, and sunn hemp is Crotolaria juncea L. Especially confusing is the phrase “Indian hemp,” which has been used both for narcotic Asian land races of C. sativa (so-called C. indica Lamarck of India) and Apocynum cannabinum L., which was used by North American Indians as a fiber plant. Cannabis sativa is a multi-purpose plant that has been domesticated for bast (phloem) fiber in the stem, a multi-purpose fixed oil in the “seeds” (achenes), and an intoxicating resin secreted by epidermal glands. The common names hemp and marijuana (much less frequently spelled marihuana) have been applied loosely to all three forms, although historically hemp has been used primarily for the fiber cultigen and its fiber preparations, and marijuana for the drug cultigen and its drug preparations. The current hemp industry is making great efforts to point out that “hemp is not marijuana.” Italicized, Cannabis refers to the biological name of the plant (only one species of this genus is commonly recognized, C. sativa L.). Non-italicized, “cannabis” is a generic abstraction, widely used as a noun and adjective, and commonly (often loosely) used both for cannabis plants and/or any or all of the intoxicant preparations made from them.
CBD may also enhance uptake of cytotoxic drugs into malignant cells. Activation of the transient receptor potential vanilloid type 2 (TRPV2) has been shown to inhibit proliferation of human glioblastoma multiforme cells and overcome resistance to the chemotherapy agent carmustine.  One study showed that coadministration of THC and CBD over single-agent usage had greater antiproliferative activity in an in vitro study with multiple human glioblastoma multiforme cell lines. In an in vitro model, CBD increased TRPV2 activation and increased uptake of cytotoxic drugs, leading to apoptosis of glioma cells without affecting normal human astrocytes. This suggests that coadministration of CBD with cytotoxic agents may increase drug uptake and potentiate cell death in human glioma cells. Also, CBD together with THC may enhance the antitumor activity of classic chemotherapeutic drugs such as temozolomide in some mouse models of cancer.[13,33] A meta-analysis of 34 in vitro and in vivo studies of cannabinoids in glioma reported that all but one study confirmed that cannabinoids selectively kill tumor cells.
Environmental sex determination is known to occur in a variety of species. Many researchers have suggested that sex in Cannabis is determined or strongly influenced by environmental factors. Ainsworth reviews that treatment with auxin and ethylene have feminizing effects, and that treatment with cytokinins and gibberellins have masculinizing effects. It has been reported that sex can be reversed in Cannabis using chemical treatment. A PCR-based method for the detection of female-associated DNA polymorphisms by genotyping has been developed.
Essential (volatile) oil in hemp is quite different from hempseed oil. Examples of commercial essential oil product products are shown in Fig. 42. The essential oil is a mixture of volatile compounds, including monoterpenes, sesquiterpenes, and other terpenoid-like compounds that are manufactured in the same epidermal glands in which the resin of Cannabis is synthesized (Meier and Mediavilla 1998). Yields are very small—about 10 L/ha (Mediavilla and Steinemann 1997), so essential oil of C. sativa is expensive, and today is simply a novelty. Essential oil of different strains varies considerably in odor, and this may have economic importance in imparting a scent to cosmetics, shampoos, soaps, creams, oils, perfumes, and foodstuffs. Switzerland has been a center for the production of essential oil for the commercial market. Narcotic strains tend to be more attractive in odor than fiber strains, and because they produce much higher numbers of flowers than fiber strains, and the (female) floral parts provide most of the essential oil, narcotic strains are naturally adapted to essential oil production. Switzerland has permitted strains with higher THC content to be grown than is allowed in other parts of the world, giving the country an advantage with respect to the essential oil market. However, essential oil in the marketplace has often been produced from low-THC Cannabis, and the THC content of essential oil obtained by steam distillation can be quite low, producing a product satisfying the needs for very low THC levels in food and other commercial goods. The composition of extracted essential oil is quite different from the volatiles released around the fresh plant (particularly limonene and alpha-pinene), so that a pleasant odor of the living plant is not necessarily indicative of a pleasant-smelling essential oil. Essential oil has been produced in Canada by Gen-X Research Inc., Regina. The world market for hemp essential oil is very limited at present, and probably also has limited growth potential.
To illustrate how hemp programs can wither without proper support, she pointed to California, where regulators continue struggling to keep up with rules and infrastructure for the more potent (and popular) marijuana industry, from lab tests to license approvals; the state's hemp operators, meanwhile, are still waiting for their official license application to come out.
A rather thorough analysis of the scope of the illicit marijuana industry in Canada for 1998 is reported at www.rcmp-grc.gc.ca/html/drugsituation.htm#Marihuana and summarized in MacLeod (1999). At least 800 tonnes (t) of marijuana were grown in Canada in 1998, representing a harvest of 4.7 million flowering plants. More than 50% of the marijuana available in Canada is grown domestically. An average mature plant was estimated to produce 170 g of “marketable substance.” The value of the Canadian crop is uncertain, but has been estimated to be in the billions of dollars annually (Heading 1998; MacLeod 1999).
Yet the DEA has stated unequivocally that it considers CBD to be illegal under the Controlled Substances Act. “CBD derived from the cannabis plant is controlled under Schedule I of the CSA because it is a naturally occurring constituent of marijuana,” Joseph Rannazzisi, the deputy assistant administrator of the DEA, told a congressional panel in June. “While there is ongoing research into a potential medical use of CBD, at this time, CBD has no currently accepted medical use in the USA.” Moreover, DEA spokesman Eduardo Chavez told the New Republic that Medical Marijuana, Inc.’s in-house opinion with regards to CBD has no merit. “The bottom line,” Chavez said, “is the oil is part of the marijuana plant, and the marijuana plant is currently a Schedule I controlled substance under federal law.”
Until 2017, products containing cannabidiol that are marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA) and could not be marketed without regulatory approval for the medical claims. CBD oil with THC content not exceeding 0.2% was legalized throughout the UK in 2017. Cannabis oil, however, remained illegal to possess, buy and sell.
Elias Anderson, one of the owners of Going Green, said representatives from HempMedsPx approached him after Krenzler published the lab’s findings on his blog. “They were like, ‘What are we gonna do about it?’” Anderson recalled, “And I was like, ‘Nothing. We have standards, and I stand behind my test results.’” Still, the company’s representatives were insistent and advised Anderson to have Kenzler take down the lab’s findings. In an email to the New Republic, Hard, the Medical Marijuana, Inc. spokesman, contended that the sample of hemp oil that Going Green Labs tested had been “tampered with” by a competitor after Krenzler obtained it. “HempMedsPX, if anything, told the lab they cannot publish results from products [for which] they had no chain of custody tracked,” Hard said, “and if they did—that could prove to be very bad for the lab.” He also characterized Krenzler and Anderson as “haters” of Medical Marijuana, Inc., and suggested that much of the criticism of the company and its products comes from commercial competitors.
μ-Opioid receptor agonists (opioids) (e.g., morphine, heroin, hydrocodone, oxycodone, opium, kratom) α2δ subunit-containing voltage-dependent calcium channels blockers (gabapentinoids) (e.g., gabapentin, pregabalin, phenibut) AMPA receptor antagonists (e.g., perampanel) CB1 receptor agonists (cannabinoids) (e.g., THC, cannabis) Dopamine receptor agonists (e.g., levodopa) Dopamine releasing agents (e.g., amphetamine, methamphetamine, MDMA, mephedrone) Dopamine reuptake inhibitors (e.g., cocaine, methylphenidate) GABAA receptor positive allosteric modulators (e.g., barbiturates, benzodiazepines, carbamates, ethanol (alcohol) (alcoholic drink), inhalants, nonbenzodiazepines, quinazolinones) GHB (sodium oxybate) and analogues Glucocorticoids (corticosteroids) (e.g., dexamethasone, prednisone) nACh receptor agonists (e.g., nicotine, tobacco, arecoline, areca nut) Nitric oxide prodrugs (e.g., alkyl nitrites (poppers)) NMDA receptor antagonists (e.g., DXM, ketamine, methoxetamine, nitrous oxide, phencyclidine, inhalants) Orexin receptor antagonists (e.g., suvorexant)
Yet when one looks at the industry more broadly, there is cause for concern. In February, as part of an investigation into the marketing claims of six hemp oil companies, the FDA analyzed 18 CBD products. What it found was disturbing: Many of these supposed CBD products were entirely lacking in CBD. Of the products tested, six contained no cannabinoids whatsoever. Another 11 contained less than 1 percent CBD. The product that tested highest in CBD, at 2.6 percent, was a capsule for dogs. In states that have legalized CBD, regulations can require CBD products to contain at least 5 percent CBD, more often 10 or 15 percent.
The high lipid-solubility of cannabinoids results in their persisting in the body for long periods of time. Even after a single administration of THC, detectable levels of THC can be found in the body for weeks or longer (depending on the amount administered and the sensitivity of the assessment method). A number of investigators have suggested that this is an important factor in marijuana's effects, perhaps because cannabinoids may accumulate in the body, particularly in the lipid membranes of neurons.
Epidiolex is the first FDA-approved treatment in the U.S. that contains a purified drug substance derived from marijuana -- CBD -- and the first treatment for Dravet syndrome. In September 2018 the FDA rescheduled cannabidiol from a C-I controlled substance to a C-V controlled substance, meaning it has a proven medical use but a low risk of abuse. This change allows Epidiolex to be marketed in the U.S.
Because of its high THC-content, in most parts of the world, including the US, Marijuana is illegal. Seeing the massive economical and medicinal benefits that Marijuana can provide, some countries and states in the US have legalized Marijuana. As the political landscape changes, hopefully more will follow, but as of now, Marijuana is generally illegal.
Prescription medicine (Schedule 4) for therapeutic use containing 2 per cent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.